New diabetes drug shows promise in early human tests
NCT ID NCT06685185
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a new medicine called NNC0363-1063 in 117 healthy volunteers and people with type 1 diabetes. The goal was to check safety, how the body processes the drug, and its effect on blood sugar. The study had three parts, including single and multiple doses, and compared the drug to placebo and standard insulins.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NNC0363-1063
What this could lead to
If it works, this could point toward a new treatment option for type 1 diabetes that helps control blood sugar.
What could go wrong
This is a very early Phase 1 trial, so the drug may not prove safe or effective. Only 117 people are enrolled, and results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Profil Institut für Stoffwechselforschung GmbH
Neuss, 41460, Germany